Abstract:Several anti-viral drugs like those used to treat human immunodeficiency virus (HIV) infections have been associated with neurotoxicity or neurodevelopmental impairments following in utero exposures. The aim of this special issue was to provide an updated overview on this topic. The published articles explored the argument using classical in vitro and animal models, and new emerging tools like cerebral organoids, covering several aspects of the proposed topic.Monnerie and colleagues explored the possibility that elvitegravir (EGV), belonging to the integrase strand transfer inhibitor (INSTI) class of antiretroviral drugs, may contribute to white matter damage in people living with HIV. The authors used mature rat cerebral cortical oligodendrocyte cultures as an in vitro model and found that EVG reduced oligodendrocyte differentiation, particularly at later stages. They investigated the involved mechanisms and found that EVG modulated the expression of sterol regulatory elementbinding protein-1 and -2 (SREBP-1 and SREBP-2), major regulators of cellular lipid metabolism. Their modulation was accompanied by reduced expression of key enzymes involved in fatty acid synthesis, while cholesterol pathways seemed unaffected. In contrast, the INSTI raltegravir (RAL) had no effect on SREBP expression. Unexpectedly, the addition of palmitate, a fatty acid, to oligodendrocyte cultures did not prevent EVG-induced inhibition of oligodendrocyte differentiation, while addition of serum albumin did prevent these effects.Rodent models are often used to evaluate neuronal toxicity of antiretroviral drugs or HIV-associated insults, however experimental observations may consistently coincide with results from human neuronal models.To overcome this problem, Starr and colleagues established an in vitro model of human induced pluripotent stem cell (iPSC)-derived cortical glutamatergic neurons. The authors first characterized their model, then assessed the effects of EVG and RAL exposure. The authors previously demonstrated that EVG but not RAL was neurotoxic in primary rat neuroglial cultures and that its toxicity was driven by the activation of the integrated stress response (ISR) (Stern et al., 2018). Here, they did not observe toxicity with either drug, measured by microtubule-associated protein 2 (MAP2) staining. However, electrophysiological measures suggested sub-lethal damage. RNA expression analysis further revealed that both INSTIs downregulated genes involved in extracellular matrix interaction, cell motility and morphogenesis.LaNoce and colleagues described the use of human iPSC-based forebrain organoids as models of human early cortical development to explore the effect of the INSTIs dolutegravir (DTG) and RAL. Previously, this model was successfully used to study the effects of Zika virus on neurodevelopment (Qian et al., 2016).Researchers treated early-stage cortical organoids with DTG or RAL within the range of cord blood concentrations. DTG exposure resulted in reduced organoid size and density of neural rosette structures and increased caspase-3 staining, while RAL had no appreciable effects. The authors performed RNA expression analyses on treated organoids and found that DTG exposure resulted in the upregulation of cellular stress, response to glucose starvation and amino acid stimulus pathways and downregulation of pathways involved in neuron differentiation and migration, CNS development and neuroblast proliferation.Immuno-histological analysis revealed reduced neurogenesis with fewer neural stem cells and postmitotic neurons. Further, they demonstrated that DTG induced ISR activation with the upregulation of downstream effectors, which may disrupt cell cycle progression and impair neurogenesis.A three-dimensional stem cell-derived brain organoid developmental model was also employed by Caiaffa and colleagues to analyze the effect of DTG with or without folic acid (FA) exposure in the earliest maturation stages. RNA expression analysis revealed that DTG exposure modulated the expression of genes involved in neurodevelopment, cell cycle, extracellular matrix, and membrane and motor proteins, as well as inducing the expression of the folate receptor FOLR1. FA exposure in the presence of DTG attenuated the alteration of gene expression, suggesting a protective role of FA. Using multimodal optical instruments, the authors found that organoids exposed to DTG presented biomechanical alterations like higher surface stiffness, lower internal stiffness and decreased volume during maturation, that were not rescued or mitigated by FA supplementation.Foster and colleagues evaluated safety and benefits of injectable long-acting DTG nano-formulation (NDTG) on fetal neurodevelopment compared to daily oral administration of native DTG in pregnant mice. The authors found that intramuscular injection of NDTG achieved therapeutic plasma DTG concentrations in pregnant dams. These pl -Abstract Truncated-

Effect of Chronic Dolutegravir Administration on the Trace Amine Profile in Wistar Rats

Clinical Profile and Adverse Effects of Dolutegravir Treatment in HIV-Positive Patients: A Prospective Observational Study

Dolutegravir-containing HIV therapy reversibly alters mitochondrial health and morphology in cultured human fibroblasts and peripheral blood mononuclear cells

Antiretroviral drug dolutegravir induces inflammation at the mouse brain barriers

Comparative Effects of Efavirenz and Dolutegravir on Metabolomic and Inflammatory Profiles, and Platelet Activation of People Living with HIV: A Pilot Study

12-week Dolutegravir treatment marginally reduces energy expenditure but does not increase body weight or alter vascular function in a murine model of Human Immunodeficiency Virus infection

Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress

Alteration in Gut Microbiome and Intestinal Barrier Function caused by Efavirenz versus Dolutegravir Treatments in Mice

Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment

Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks

Different effects of the companion antiretroviral drugs on dolutegravir trough concentrations: a focus on novel dual regimens

Correlation Analysis of DNA UGT1A1 Gene Expression in Hyperbilirubinemia and Central Nervous System-Related Adverse Reactions Following Oral Dolutegravir Administration

A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV

Impact of Dolutegravir plus Lamivudine as First-Line Antiretroviral Treatment on HIV-1 Reservoir and Inflammatory Markers in Peripheral Blood

Editorial: Antiviral drugs: neurotoxicity and neurodevelopmental effects

Effect of Dolutegravir-Based First-Line Antiretroviral Therapy on Mother-to-Child Transmission of HIV Among HIV-Exposed Infants in Ethiopia: a Before-and-After Study

Effect of dolutegravir on ferritin, iron, and C-reactive protein among people living with HIV and co-infections

A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients

Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review

Population Pharmacokinetic Analysis of Dolutegravir in Treatment‐Experienced Adults Living with HIV‐1

Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa